Suppr超能文献

乳腺癌细胞的长期药物选择和癌症干细胞特征的富集。

Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

机构信息

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. doi: 10.1093/jnci/djq361. Epub 2010 Oct 8.

Abstract

BACKGROUND

Cancer stem cells are presumed to have virtually unlimited proliferative and self-renewal abilities and to be highly resistant to chemotherapy, a feature that is associated with overexpression of ATP-binding cassette transporters. We investigated whether prolonged continuous selection of cells for drug resistance enriches cultures for cancer stem-like cells.

METHODS

Cancer stem cells were defined as CD44+/CD24⁻ cells that could self-renew (ie, generate cells with the tumorigenic CD44+/CD24⁻ phenotype), differentiate, invade, and form tumors in vivo. We used doxorubicin-selected MCF-7/ADR cells, weakly tumorigenic parental MCF-7 cells, and MCF-7/MDR, an MCF-7 subline with forced expression of ABCB1 protein. Cells were examined for cell surface markers and side-population fractions by microarray and flow cytometry, with in vitro invasion assays, and for ability to form mammospheres. Xenograft tumors were generated in mice to examine tumorigenicity (n = 52). The mRNA expression of multidrug resistance genes was examined in putative cancer stem cells and pathway analysis of statistically significantly differentially expressed genes was performed. All statistical tests were two-sided.

RESULTS

Pathway analysis showed that MCF-7/ADR cells express mRNAs from ABCB1 and other genes also found in breast cancer stem cells (eg, CD44, TGFB1, and SNAI1). MCF-7/ADR cells were highly invasive, formed mammospheres, and were tumorigenic in mice. In contrast to parental MCF-7 cells, more than 30% of MCF-7/ADR cells had a CD44+/CD24⁻ phenotype, could self-renew, and differentiate (ie, produce CD44+/CD24⁻ and CD44+/CD24+ cells) and overexpressed various multidrug resistance-linked genes (including ABCB1, CCNE1, and MMP9). MCF-7/ADR cells were statistically significantly more invasive in Matrigel than parental MCF-7 cells (MCF-7 cells = 0.82 cell per field and MCF-7/ADR = 7.51 cells per field, difference = 6.69 cells per field, 95% confidence interval = 4.82 to 8.55 cells per field, P < .001). No enrichment in the CD44+/CD24⁻ or CD133+ population was detected in MCF-7/MDR.

CONCLUSION

The cell population with cancer stem cell characteristics increased after prolonged continuous selection for doxorubicin resistance.

摘要

背景

癌症干细胞被认为具有几乎无限的增殖和自我更新能力,并且对化疗高度耐药,这一特征与三磷酸腺苷结合盒转运蛋白的过度表达有关。我们研究了长期连续选择耐药细胞是否会富集具有癌症干细胞样特性的细胞。

方法

癌症干细胞被定义为能够自我更新(即产生具有肿瘤形成性 CD44+/CD24⁻表型的细胞)、分化、侵袭和体内形成肿瘤的 CD44+/CD24⁻细胞。我们使用多柔比星选择的 MCF-7/ADR 细胞、弱致瘤性亲本 MCF-7 细胞和 MCF-7/MDR(一种强制表达 ABCB1 蛋白的 MCF-7 亚系)进行研究。通过微阵列和流式细胞术检查细胞表面标志物和侧群分数,进行体外侵袭试验,并检查形成乳腺球体的能力。在小鼠中生成异种移植肿瘤以检查致瘤性(n=52)。在假定的癌症干细胞中检查多药耐药基因的 mRNA 表达,并对统计学上差异表达基因进行途径分析。所有统计检验均为双侧检验。

结果

途径分析表明,MCF-7/ADR 细胞表达 ABCB1 和其他在乳腺癌干细胞中也发现的基因的 mRNA(例如 CD44、TGFB1 和 SNAI1)。MCF-7/ADR 细胞具有高侵袭性,形成乳腺球体,并在小鼠中具有致瘤性。与亲本 MCF-7 细胞相比,超过 30%的 MCF-7/ADR 细胞具有 CD44+/CD24⁻表型,能够自我更新并分化(即产生 CD44+/CD24⁻和 CD44+/CD24+细胞),并过度表达各种多药耐药相关基因(包括 ABCB1、CCNE1 和 MMP9)。MCF-7/ADR 细胞在 Matrigel 中的侵袭性明显高于亲本 MCF-7 细胞(MCF-7 细胞=0.82 个细胞/视野,MCF-7/ADR=7.51 个细胞/视野,差异=6.69 个细胞/视野,95%置信区间=4.82 至 8.55 个细胞/视野,P<0.001)。在 MCF-7/MDR 中未检测到 CD44+/CD24⁻或 CD133+群体的富集。

结论

在长期连续选择多柔比星耐药后,具有癌症干细胞特征的细胞群体增加。

相似文献

1
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. doi: 10.1093/jnci/djq361. Epub 2010 Oct 8.
2
SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
BMC Cancer. 2010 Aug 6;10:411. doi: 10.1186/1471-2407-10-411.
4
A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
PLoS One. 2015 Jan 30;10(1):e0116747. doi: 10.1371/journal.pone.0116747. eCollection 2015.
7
Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
Genet Mol Res. 2015 Mar 27;14(1):2347-55. doi: 10.4238/2015.March.27.20.

引用本文的文献

1
Advances in research on RNA methylation and cancer radiotherapy resistance.
Front Oncol. 2025 Jul 31;15:1596541. doi: 10.3389/fonc.2025.1596541. eCollection 2025.
2
Doxorubicin Stability-indicating Method and its Main Degradation Products In vitro Toxicity.
AAPS J. 2025 Jul 8;27(5):117. doi: 10.1208/s12248-025-01104-y.
4
Circular RNAs in cancer stem cells: Insights into their roles and mechanisms (Review).
Int J Mol Med. 2025 Mar;55(3). doi: 10.3892/ijmm.2025.5491. Epub 2025 Jan 24.
5
DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer.
Cancer Res. 2025 Mar 3;85(5):838-847. doi: 10.1158/0008-5472.CAN-24-3304.
7
Hyperthermia/glutathione-triggered ferritin nanoparticles amplify the ferroptosis for synergistic tumor therapy.
Mater Today Bio. 2024 May 4;26:101085. doi: 10.1016/j.mtbio.2024.101085. eCollection 2024 Jun.
9
ABCB1 Regulates Immune Genes in Breast Cancer.
Breast Cancer (Dove Med Press). 2023 Nov 13;15:801-811. doi: 10.2147/BCTT.S421213. eCollection 2023.
10
The ALKBH5/SOX4 axis promotes liver cancer stem cell properties via activating the SHH signaling pathway.
J Cancer Res Clin Oncol. 2023 Nov;149(17):15499-15510. doi: 10.1007/s00432-023-05309-6. Epub 2023 Aug 30.

本文引用的文献

1
ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis.
Biochem Biophys Res Commun. 2010 Jun 11;396(4):843-8. doi: 10.1016/j.bbrc.2010.04.170. Epub 2010 May 5.
4
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.
Clin Cancer Res. 2010 Jan 1;16(1):45-55. doi: 10.1158/1078-0432.CCR-09-1630. Epub 2009 Dec 22.
5
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.
6
Identification of selective inhibitors of cancer stem cells by high-throughput screening.
Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
7
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.
8
ABC transporters, drug resistance, and cancer stem cells.
J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):3-9. doi: 10.1007/s10911-009-9109-9. Epub 2009 Feb 18.
9
Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.
Cancer Immunol Immunother. 2009 Aug;58(8):1185-94. doi: 10.1007/s00262-008-0623-1. Epub 2008 Dec 2.
10
Are stem-like cells responsible for resistance to therapy in breast cancer?
Breast Dis. 2008;29:83-9. doi: 10.3233/bd-2008-29109.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验